Clinical Trials Directory

Trials / Completed

CompletedNCT01131832

Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
71 (actual)
Sponsor
University of Manitoba · Academic / Other
Sex
All
Age
30 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The substantial range of individual responsiveness to plant sterols has important ramifications. Marked differences across individuals in particular aspects of the cholesterol metabolic pathway must alter the impact of plant sterol consumption. As such, a pronounced need exists to understand the genetic and metabolic factors that explain the substantial degree of heterogeneity in response of lipid concentrations to plant sterols across individuals. The primary focus of this trial is to delineate the impact of differing cholesterol synthesis levels on response of LDL-C and other plasma lipids to plant sterol consumption. Participants pre-identified as high or low endogenous cholesterol synthesizers, according to their screening level of lathosterol to cholesterol ratios, will be given PS or a placebo containing margarine to consume under supervision for 4 weeks in a crossover design. The trial will characterize the responsiveness of the participants' total, LDL, and HDL cholesterol, as well as triacylglycerol (TG) concentrations, to plant sterol consumption. This research will determine if cholesterol synthesis phenotype predicts the responsiveness of lipids to plant sterol consumption. Variations in candidate genes involved in cholesterol metabolism will also be investigated in order to find associations with both cholesterol metabolism phenotypes and responsiveness of lipids to plant sterols. The output of this research will be to advance the knowledge of which genetic factors influence the degree of cardiovascular benefit derived from plant sterols through lipid lowering.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPlant sterol
DIETARY_SUPPLEMENTPlacebo

Timeline

Start date
2010-09-01
Primary completion
2012-02-01
Completion
2012-02-01
First posted
2010-05-27
Last updated
2017-05-09

Locations

2 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT01131832. Inclusion in this directory is not an endorsement.